Antimicrobial Resistance in Emerging, Opportunistic, and Atypical Pathogens

Antimicrobial resistance (AMR) in classical pathogens is well-documented, however there is growing concern for clinical resistance and treatment failure of atypical, opportunistic, and emerging species of bacteria, fungi, parasites, and viruses. These organisms often possess unique cellular structures, environmental niches, and metabolic profiles that facilitate their resistance to antimicrobial treatment. Additionally, many of these pathogens exploit atypical host reservoirs, persist in intracellular compartments, or form specialized biofilms. These mechanisms are known to further complicate therapeutic approaches and lead to adverse patient outcomes. High-priority organisms are atypical bacteria and non-bacterial pathogens.This Research Topic aims to highlight cutting-edge research defining the cellular, molecular, and ecological mechanisms underpinning AMR in these high-consequence, understudied organisms. The pathogens highlighted in this collection represent a critical and rapidly expanding frontier of infectious disease, including neglected pathogens. They disproportionately affect immunocompromised patients, those in intensive care settings, patients exposed to invasive medical devices, and populations exposed to environmental reservoirs.To gather further insights in this dynamic field, we welcome articles addressing, but not limited to, the following themes:• Drug resistance in atypical/emerging bacterial pathogens such as Brucella, Rickettsia, nontuberculosis mycobacteria, Elizabethkingia species• Antifungal resistance, including novel mechanisms, in pathogens such as Candida auris, Aspergillus fumigatus, Trichophyton indotineae• Antiparasitic resistance, including novel mechanisms, in pathogens such as Toxoplasma gondii, Plasmodium species, Giardia lamblia, Leishmania species• Emerging antiviral use and resistance, including novel mechanisms, in viral infections such as Ebola virus, Dengue virus, and Respiratory Syncytial Virus (RSV)• Clinical cases of treatment failure due to resistance, focusing on opportunistic, atypical, or emerging pathogens• Systematic reviews investigating the epidemiological impact of antimicrobial resistance on specific microbes, with focus on certain patient populations, healthcare institutions, etc.• Novel antimicrobials, phages etc. to help treat these microbes, whether in the lab, or in clinical practice• Advances in technology for studying AMR, such as genomic, molecular, and high-throughput screening methods• Host–pathogen interactions and biofilm-related resistance mechanisms• Public health, infection control, antimicrobial stewardship, and surveillance approaches tailored to emerging AMR threats• New tools for prevention and infection control, including vaccines, public health interventions, and surveillance approachesBy bringing together experts across microbiology, genomics, pathogenesis, clinical practice, and therapeutics, the collection will accelerate our understanding of resistance mechanisms, equip clinicians with knowledge on possible causes of infections recalcitrant to typical treatment and alternative therapies, and stimulate innovative solutions. Topic editors: KAMAL EL BISSATI, Erin Honsa, Nicholas Streck Source: https://www.frontiersin.org/research-topics/78156/antimicrobial-resistance-in-emerging-opportunistic-and-atypical-pathogens